18 results about "Canine coronavirus" patented technology

The invention provides a canine coronavirus strain as well as an inactivated vaccine and application thereof. The canine coronavirus strain is named as CCoV2015, and the genome full-length cDNA sequence of the canine coronavirus strain is as shown in SEQ ID NO. 1. The canine coronavirus strain is collected from intestinal tissues of naturally diseased dogs, sequence comparative analysis shows that the strain is a novel canine coronavirus strain, the infection ability of the strain is high, the strain is highly homologous with canine coronavirus strains separated in recent years, and the canine coronavirus strain is inactivated to prepare the canine coronavirus vaccine. Meanwhile, the canine coronavirus vaccine also fills the blank of a single canine coronavirus vaccine, and plays a very important role in prevention of canine coronavirus.

The present invention discloses a canine coronavirus attenuated strain CCoVAS22 and its application, and relates to the field of biomedicine technology. The canine coronavirus attenuated strain CCoVAS22 was deposited in the China Center for Type Culture Collection on July 12, 2024, and the deposit address is Wuhan University, Wuhan, China, and the deposit number is CCTCC NO: V202413. The present invention utilizes the technical means of cross-passaging in MDCK and CRFK cell lines to obtain an independently isolated CCoVAS22 strain, which has the advantages of high toxicity and stable passage on cells. After inactivation by β-propiolactone, it has the characteristics of high safety and good immunogenicity. It can be used as a candidate strain for CCoV inactivated vaccine, which can alleviate the problem of the small number of canine coronavirus isolates in China to a certain extent, and provide technical support for the prevention of diseases caused by canine coronavirus.

The invention discloses a monoclonal antibody for resisting canine coronavirus N protein, a detection reagent and application of the monoclonal antibody and the detection reagent. The monoclonal antibody for resisting the canine coronavirus N protein comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID No.2. The monoclonal antibody with high affinity and detection sensitivity to canine coronavirus N protein lays a foundation for research, development and popularization of colloidal gold test strips and fluorescence immunoassay test strips.

The application discloses application of a plant extract, tribuloside, in preparation of a medicine for resisting canine coronavirus, and relates to the technical field of biological medicine.The application finds that the plant extract, tribuloside, has the activity of resisting canine coronavirus.The plant extract in the application is derived from a natural plant, and has the advantages of low toxicity and good biocompatibility, as compared with chemical medicines.The application provides technical support for development of novel, effective, safe and side-effect-free medicine preparations for preventing and treating canine coronavirus.

The application discloses application of monensin in preparation of anti-coronavirus drugs, relates to the technical field of new monensin purposes, and the coronavirus has a ribosome frameshift translation regulation mechanism, monensin is used for inhibiting ribosome frameshift, and then inhibiting the coronavirus proliferation. For feline infectious peritonitis virus, the effective concentration of monensin is 0.1 muM-10 muM. For canine coronavirus, the effective concentration of monensin is 0.5 muM-10 muM. The application has the following advantages: small drug resistance risk; low effective concentration; and convenient administration.

The application belongs to the technical field of biological detection, and particularly relates to a combination of monoclonal antibodies against nucleocapsid protein of canine distemper virus and application. The combination is composed of monoclonal antibodies 1C8 and 1G8, and the sequences of the heavy chain and light chain variable region complement determining regions are clear (as shown in SEQ ID NO. 1-12, respectively), which endow the combination with high affinity and specificity. It has been verified that the combination can specifically recognize CDV-NP, and has no cross reaction with irrelevant antigens such as canine parainfluenza virus, canine coronavirus and canine parvovirus, thereby guaranteeing the specificity of detection from the source. The antibody combination can be used for preparing colloidal gold detection test strips, kits and other detection tools. The colloidal gold detection test strip based on the double antibody sandwich method uses 1C8 as a capture antibody and 1G8 as a labeled antibody, and is simple to operate, intuitive in results, does not require professional equipment, and is suitable for rapid screening in the field.

The present invention discloses a monoclonal antibody for canine coronavirus N protein, an immune colloidal gold test strip, and a preparation method thereof, and belongs to the field of biological detection technology. The present invention provides a hybridoma cell line, the hybridoma cell line is named 4A8, the deposit number of the 4A8 is CCTCC NO: C2024304, and the monoclonal antibody 4A8 secreted by the hybridoma cell line. Also disclosed is the use of the hybridoma cell line or the monoclonal antibody 4A8 in the preparation of a detection reagent or a detection kit for canine coronavirus. In addition, the present invention also discloses an immune colloidal gold test strip for detecting canine coronavirus N protein and a preparation method thereof. Among the 47 clinical samples tested, the total compliance rate of the colloidal gold test strip was 89.36%. The CCoV colloidal gold test strip detection method established by the present invention is convenient and sensitive, and is of great significance for the diagnosis, prevention and control of canine coronavirus disease.

The invention provides a reagent and a kit for detecting canine coronavirus nucleic acid and application of the reagent and the kit. The reagent comprises a reagent for detecting a first region of the canine coronavirus, and the first region is selected from any fragment in SEQ ID NO: 1. By applying the reagent or the kit provided by the invention, the canine coronavirus can be accurately, quickly and sensitively identified.

The invention discloses application of monensin in preparation of an anti-coronavirus drug, and relates to the technical field of new application of monensin, coronavirus has a translation regulation mechanism of ribosome frame shift, and monensin is used for inhibiting ribosome frame shift so as to inhibit proliferation of the coronavirus. For the cat infectious peritonitis virus, the effective concentration of the monensin is 0.1 mu M to 10 mu M. For canine coronavirus, the effective concentration of the monensin is 0.5-10 [mu] M. The invention has the following advantages: the drug resistance risk is small; the effective concentration is low; the administration is convenient.

This application belongs to the field of in vitro detection technology, specifically relating to a fluorescent immunochromatographic kit for detecting canine parvovirus, canine coronavirus, and Giardia virus, as well as its preparation method and application. This application provides a fluorescent immunochromatographic kit for detecting canine parvovirus, canine coronavirus, and Giardia virus. Through a triple detection system design, it can simultaneously detect three important pathogens: canine parvovirus, canine coronavirus, and Giardia virus, improving detection efficiency and providing more comprehensive information for clinical diagnosis. Furthermore, by adding metal chelating agents and lysis agents to the sample diluent, metal ion impurities in the sample that cause non-specific binding can be specifically chelated, effectively eliminating interference and significantly improving the detection rate of the target pathogens while enhancing detection sensitivity, thus meeting the needs of rapid on-site screening in canine clinics.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

The invention provides a primer and a fluorescent probe combination capable of simultaneously detecting nucleic acids of six pathogens of a dog and an application of the primer and the fluorescent probe combination. The primer and fluorescent probe combination comprises a group of primer probe combination for detecting three dog digestive tract pathogens, namely canine parvovirus, canine bordetella and canine adenovirus, and a group of primer probe combination for detecting three dog respiratory tract pathogens, namely canine distemper virus, canine coronavirus and canine parainfluenza virus. The invention also provides a six-linked fluorescent RT-qPCR detection method and a kit using the primer probe combination. According to the method, one group of primer probe combination can be selected for detection, or two groups of primer probe combinations can be selected for detection at the same time. According to the method disclosed by the invention, the signal intensity amplified by each three channels of two tubes is monitored and output in real time, and qualitative analysis of common canine pathogen detection is realized. Operation is convenient and fast, sensitivity is high, and cost is low.

This invention discloses the application of plant extracts in the preparation of drugs against canine coronavirus, belonging to the field of biomedical technology. The invention found that plant extracts—shikimic acid, phlorizin, caffeic acid, tribulus terrestris saponins, berberine hydrochloride, and apple polyphenols—possess anti-canine coronavirus activity, with phlorizin showing the most significant effect. Phlorizin exhibits antiviral activity in three aspects: direct killing, inhibition of viral adsorption, and inhibition of viral growth, with the inhibition of viral growth being the most significant. Phlorizin acts on the EC50 cells of cCoV. 50 The concentration was 0.616 mg / L. The plant extract of this invention is derived from natural plants and, compared to chemical drugs, has the advantages of low toxicity and good biocompatibility. This invention provides technical support for the development of novel, effective, safe, and side-effect-free pharmaceutical formulations for the prevention and treatment of canine coronavirus.

The application discloses a quadruple RT-qPCR method for simultaneously detecting canine digestive tract viruses, a kit and application, and the real-time fluorescent quantitative PCR detection kit comprises PCR primer probes, the PCR primer probes comprise forward PCR amplification primers, reverse PCR amplification primers and detection probes respectively for canine parvovirus, canine coronavirus, canine adenovirus type 1 and canine rotavirus; the sequences are shown in SEQ ID NO. 1 to SEQ ID NO. 12, respectively, the application can detect canine parvovirus, canine coronavirus, canine adenovirus type 1 and canine rotavirus, has very high sensitivity and specificity, and is favorable for early diagnosis or treatment of sick dogs.

This invention discloses a triple lyophilized fluorescent PCR rapid detection kit for canine distemper virus, canine coronavirus, and canine parvovirus, belonging to the field of rapid detection kit technology. It includes a housing, protective components, and a sample collection mechanism. The back of the housing is symmetrically fitted with hinges via bolts. This triple lyophilized fluorescent PCR rapid detection kit for canine distemper virus, canine coronavirus, and canine parvovirus, through its primer, fluorescent probe, and reagent carrier components and sample collection mechanism, enables the rapid screening of three highly pathogenic canine viruses (canine distemper virus CDV, canine coronavirus CCV, and canine parvovirus CPV) using a lyophilization process based on quantitative real-time PCR technology.

The application belongs to the technical field of biomedical detection, and discloses an antibody pair against canine coronavirus N protein, a preparation method thereof, a nucleic acid molecule, a cell strain and application. The antibody pair or antigen binding fragment thereof comprises a first antibody or antigen binding fragment thereof, wherein the first antibody or antigen binding fragment thereof comprises amino acid sequences of heavy chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 1-3, and amino acid sequences of light chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 4-6; and a second antibody or antigen binding fragment thereof, wherein the second antibody or antigen binding fragment thereof comprises amino acid sequences of heavy chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 7-9, and amino acid sequences of light chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 10-12. The antibody pair provided by the application has a high titer, and has strong binding capacity with canine coronavirus N protein, and can realize high specificity and high sensitivity detection of canine coronavirus without interference of other viruses and drugs.

The application discloses a canine leptospira, icterohaemorrhagia leptospira and canine coronavirus triple inactivated vaccine. The application is prepared by adding adjuvant after inactivation of the canine leptospira, icterohaemorrhagia leptospira and canine coronavirus epidemic strain separated in China. The application relates to a pathogen separation culture, identification, inactivation method, production process, vaccine storage and immunization method. The canine triple inactivated vaccine is used for preventing canine leptospira disease, icterohaemorrhagia leptospira disease and canine coronavirus disease, and high antibodies can be generated after immunization of the canine, and the high antibodies have a good protective effect on virulent attack. The leptospira is a zoonosis, the canine is a companion animal of human, and the pet canine is in close contact with human, so the triple inactivated vaccine has good social benefits and important public health significance.